nach oben

Clinical Rheumatology

Erschienen in:

08.09.2023 | REVIEW ARTICLE

Association between primary Sjögren’s syndrome and gut microbiota disruption: a systematic review and meta-analysis

verfasst von: Yue Shen, Xue Yu, Qiao Wang, Xinyi Yao, Dingqi Lu, Donghai Zhou, Xinchang Wang

Erschienen in: Clinical Rheumatology | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Evidence of gut microbiota disruption for numerous autoimmune diseases has accumulated. Recently, the relationship between the microbiota and primary Sjögren’s disease has been increasingly investigated but has yet to be systematically elucidated. Therefore, a meta-analysis of publications dealing on topic was conducted. Case–control studies comparing primary Sjögren’s syndrome patients and healthy controls (HCs) were systematically searched in nine databases from inception to March 1, 2023. The primary result quantitatively evaluated in this meta-analysis was the α-diversity. The secondary results qualitatively extracted and analyzed were the β-diversity and relative abundance. In total, 22 case–control studies covering 915 pSS patients and 2103 HCs were examined. The quantitative analysis revealed a slight reduction in α-diversity in pSS patients compared to HCs, with a lower Shannon–Wiener index (SMD = − 0.46, (− 0.68, − 0.25), p < 0.0001, I² = 71%), Chao1 richness estimator (SMD = − 0.59, (− 0.86, − 0.32), p < 0.0001, I² = 81%), and ACE index (SMD = − 0.92, (− 1.64, − 0.19), p = 0.01, I² = 86%). However, the Simpson index (SMD = 0.01, (− 0.43, 0.46) p = 0.95, I² = 86%) was similar in the two groups. The β-diversity significantly differed between pSS patients and HCs. Variations in the abundance of specific microbes and their metabolites and potential functions contribute to the pSS pathogenesis. Notably, the abundance of the phylum Firmicutes decreased, while that of Proteobacteria increased. SCFA-producing microbes including Ruminococcaceae, Lachnospiraceae, Faecalibacterium, Butyricicoccus, and Eubacterium hallii were depleted. In addition to diversity, the abundances of some specific microbes were related to clinical parameters. According to this systematic review and meta-analysis, gut microbiota dysbiosis, including reduced diversity, was associated with proinflammatory bacterium enrichment and anti-inflammatory bacterium depletion in pSS patients. Further research on the relationship between the gut microbiota and pSS is warranted.

Nur mit Berechtigung zugänglich

Brito-Zerón P, Baldini C, Bootsma H, Bowman SJ, Jonsson R, Mariette X et al (2016) Sjögren syndrome. Nat Rev Dis Primers 2:16047. https://doi.org/10.1038/nrdp.2016.47CrossRefPubMed

Jonsson R, Vogelsang P, Volchenkov R, Espinosa A, Wahren-Herlenius M, Appel S (2011) The complexity of Sjögren’s syndrome: novel aspects on pathogenesis. Immunol Lett 141(1):1–9. https://doi.org/10.1016/j.imlet.2011.06.007CrossRefPubMed

Mavragani CP, Moutsopoulos HM (2010) The geoepidemiology of Sjögren’s syndrome. Autoimmun Rev 9(5):A305–A310. https://doi.org/10.1016/j.autrev.2009.11.004CrossRefPubMed

Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F et al (2015) Epidemiology of primary Sjögren’s syndrome: a systematic review and meta-analysis. Ann Rheum Dis 74(11):1983–9. https://doi.org/10.1136/annrheumdis-2014-205375CrossRefPubMed

Manfrè V, Chatzis LG, Cafaro G, Fonzetti S, Calvacchi S, Fulvio G et al (2022) Sjögren’s syndrome: one year in review 2022. Clin Exp Rheumatol 40(12):2211–24. https://doi.org/10.55563/clinexprheumatol/43z8gu

Human Microbiome Project Consortium (2012) A framework for human microbiome research. Nature 486(7402):215–21. https://doi.org/10.1038/nature11209

De Luca F, Shoenfeld Y (2019) The microbiome in autoimmune diseases. Clin Exp Immunol 195(1):74–85. https://doi.org/10.1111/cei.13158CrossRefPubMed

Van de Wiele T, Van Praet JT, Marzorati M, Drennan MB, Elewaut D (2016) How the microbiota shapes rheumatic diseases. Nat Rev Rheumatol 12(7):398–411. https://doi.org/10.1038/nrrheum.2016.85CrossRefPubMed

Coit P, Sawalha AH (2016) The human microbiome in rheumatic autoimmune diseases: a comprehensive review. Clin Immunol 170:70–9. https://doi.org/10.1016/j.clim.2016.07.026CrossRefPubMed

10.

Lee YK, Mazmanian SK (2010) Has the microbiota played a critical role in the evolution of the adaptive immune system? Science 330(6012):1768–73. https://doi.org/10.1126/science.1195568CrossRefPubMedPubMedCentral

11.

Kamada N, Seo SU, Chen GY, Núñez G (2013) Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol 13(5):321–35. https://doi.org/10.1038/nri3430CrossRefPubMed

12.

Doaré E, Héry-Arnaud G, Devauchelle-Pensec V, Alegria GC (2021) Healthy patients are not the best controls for microbiome-based clinical studies: example of Sjögren’s syndrome in a systematic review. Front Immunol 12:699011. https://doi.org/10.3389/fimmu.2021.699011CrossRefPubMedPubMedCentral

13.

de Paiva CS, Jones DB, Stern ME, Bian F, Moore QL, Corbiere S et al (2016) Altered mucosal microbiome diversity and disease severity in Sjögren syndrome. Sci Rep 6:23561. https://doi.org/10.1038/srep23561CrossRefPubMedPubMedCentral

14.

Verstappen GM, Pringle S, Bootsma H, Kroese FGM (2021) Epithelial-immune cell interplay in primary Sjögren syndrome salivary gland pathogenesis. Nat Rev Rheumatol 17(6):333–48. https://doi.org/10.1038/s41584-021-00605-2CrossRefPubMedPubMedCentral

15.

Kim DS, Woo JS, Min HK, Choi JW, Moon JH, Park MJ et al (2021) Short-chain fatty acid butyrate induces IL-10-producing B cells by regulating circadian-clock-related genes to ameliorate Sjögren’s syndrome. J Autoimmun 119:102611. https://doi.org/10.1016/j.jaut.2021.102611CrossRefPubMed

16.

Szymula A, Rosenthal J, Szczerba BM, Bagavant H, Fu SM, Deshmukh US (2014) T cell epitope mimicry between Sjögren’s syndrome antigen A (SSA)/Ro60 and oral, gut, skin and vaginal bacteria. Clin Immunol 152(1–2):1–9. https://doi.org/10.1016/j.clim.2014.02.004CrossRefPubMedPubMedCentral

17.

Tsigalou C, Stavropoulou E, Bezirtzoglou E (2018) Current insights in microbiome shifts in Sjogren’s syndrome and possible therapeutic interventions. Front Immunol 9:1106. https://doi.org/10.3389/fimmu.2018.01106CrossRefPubMedPubMedCentral

18.

van der Meulen TA, Kroese FGM, Bootsma H, Spijkervet FKL, Vissink A (2020) Current insights into the relationship between the gut microbiome and Sjögren’s syndrome. Microb Cell Fact 19(1):210. https://doi.org/10.1186/s12934-020-01471-5CrossRefPubMedPubMedCentral

19.

Moon J, Choi SH, Yoon CH, Kim MK (2020) Gut dysbiosis is prevailing in Sjögren’s syndrome and is related to dry eye severity. PloS one 15(2):e0229029. https://doi.org/10.1371/journal.pone.0229029CrossRefPubMedPubMedCentral

20.

van der Meulen TA, Harmsen HJM, Vila AV, Kurilshikov A, Liefers SC, Zhernakova A et al (2019) Shared gut, but distinct oral microbiota composition in primary Sjögren’s syndrome and systemic lupus erythematosus. J Autoimmun 97:77–87. https://doi.org/10.1016/j.jaut.2018.10.009CrossRefPubMed

21.

Wang X, Pang K, Wang J, Zhang B, Liu Z, Lu S et al (2022) Microbiota dysbiosis in primary Sjögren’s syndrome and the ameliorative effect of hydroxychloroquine. Cell Rep 40(11):111352. https://doi.org/10.1016/j.celrep.2022.111352CrossRefPubMed

22.

Wu GL, Lu HF, Chen YL, Wang Q, Cao H, Li TY (2019) Changes of intestinal microecology in patients with primary Sjogren’s syndrome after therapy of Yangyin Yiqi Huoxue recipe (). Chin J Integr Med 25(9):654–62. https://doi.org/10.1007/s11655-019-2939-4CrossRefPubMed

23.

Bellocchi C, Fernández-Ochoa Á, Montanelli G, Vigone B, Santaniello A, Quirantes-Piné R et al (2019) Identification of a shared microbiomic and metabolomic profile in systemic autoimmune diseases. J Clin Med 8(9):1291. https://doi.org/10.3390/jcm8091291

24.

Cano-Ortiz A, Laborda-Illanes A, Plaza-Andrades I, Membrillo Del Pozo A, Villarrubia Cuadrado A, Rodríguez Calvo de Mora M et al (2020) Connection between the gut microbiome, systemic inflammation, gut permeability and FOXP3 expression in patients with primary Sjögren’s syndrome. Int J Mol Sci 21(22). https://doi.org/10.3390/ijms21228733

25.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical research ed) 372:n71. https://doi.org/10.1136/bmj.n71CrossRefPubMed

26.

Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25(9):603–5. https://doi.org/10.1007/s10654-010-9491-zCrossRefPubMed

27.

Chu XJ, Cao NW, Zhou HY, Meng X, Guo B, Zhang HY et al (2021) The oral and gut microbiome in rheumatoid arthritis patients: a systematic review. Rheumatology 60(3):1054–66. https://doi.org/10.1093/rheumatology/keaa835CrossRefPubMed

28.

Shen T, Yue Y, He T, Huang C, Qu B, Lv W et al (2021) The association between the gut microbiota and Parkinson’s disease, a meta-analysis. Front Aging Neurosci 13:636545. https://doi.org/10.3389/fnagi.2021.636545CrossRefPubMedPubMedCentral

29.

Zhou Z, Shi B, Xu Y, Zhang J, Liu X, Zhou X et al (2023) Neural stem/progenitor cell therapy for Alzheimer disease in preclinical rodent models: a systematic review and meta-analysis. Stem Cell Res Ther 14(1):3. https://doi.org/10.1186/s13287-022-03231-1CrossRefPubMedPubMedCentral

30.

Bakbergenuly I, Hoaglin DC, Kulinskaya E (2020) Estimation in meta-analyses of mean difference and standardized mean difference. Stat Med 39(2):171–91. https://doi.org/10.1002/sim.8422CrossRefPubMed

31.

Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J et al (2011) Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ (Clinical research ed) 343:d4002. https://doi.org/10.1136/bmj.d4002CrossRefPubMed

32.

Chavalarias D, Wallach JD, Li AH, Ioannidis JP (2016) Evolution of reporting p values in the biomedical literature, 1990–2015. Jama 315(11):1141–8. https://doi.org/10.1001/jama.2016.1952CrossRefPubMed

33.

Goodman CF, Doan T, Mehra D, Betz J, Locatelli E, Mangwani-Mordani S et al (2022) Case-control study examining the composition of the gut microbiome in individuals with and without immune-mediated dry eye. Cornea. https://doi.org/10.1097/ico.0000000000003195CrossRefPubMedPubMedCentral

34.

Wang F, Zhufeng Y, Chen Z, Xu J, Cheng Y (2023) The composition and function profile of the gut microbiota of patients with primary Sjögren’s syndrome. Clin Rheumatol. https://doi.org/10.1007/s10067-022-06451-1CrossRefPubMedPubMedCentral

35.

Schaefer L, Trujillo-Vargas CM, Midani FS, Pflugfelder SC, Britton RA, de Paiva CS (2022) Gut microbiota from Sjögren syndrome patients causes decreased T regulatory cells in the lymphoid organs and desiccation-induced corneal barrier disruption in mice. Front Med 9:852918. https://doi.org/10.3389/fmed.2022.852918CrossRef

36.

Yang L, Xiang Z, Zou J, Zhang Y, Ni Y, Yang J (2022) Comprehensive analysis of the relationships between the gut microbiota and fecal metabolome in individuals with primary Sjogren’s syndrome by 16S rRNA sequencing and LC-MS-based metabolomics. Front Immunol 13:874021. https://doi.org/10.3389/fimmu.2022.874021CrossRefPubMedPubMedCentral

37.

Mendez R, Watane A, Farhangi M, Cavuoto KM, Leith T, Budree S et al (2020) Gut microbial dysbiosis in individuals with Sjögren’s syndrome. Microb Cell Fact 19(1):90. https://doi.org/10.1186/s12934-020-01348-7CrossRefPubMedPubMedCentral

38.

Mandl T, Marsal J, Olsson P, Ohlsson B, Andréasson K (2017) Severe intestinal dysbiosis is prevalent in primary Sjögren’s syndrome and is associated with systemic disease activity. Arthritis Res Ther 19(1):237. https://doi.org/10.1186/s13075-017-1446-2CrossRefPubMedPubMedCentral

39.

Wang X, Wang J, Guo W, Zhou Y, Sun C, Li Z et al (2020) Characteristics of intestinal flora in patients with primary Sjögren syndrome. Nan fang yi ke da xue xue bao 40(7):949–57. https://doi.org/10.12122/j.issn.1673-4254.2020.07.06. in Chinese

40.

Xin X, Wang Q, Qing J, Song W, Gui Y, Li X et al (2022) Th17 cells in primary Sjögren’s syndrome negatively correlate with increased Roseburia and Coprococcus. Front Immunol 13:974648. https://doi.org/10.3389/fimmu.2022.974648CrossRefPubMedPubMedCentral

41.

Jia XM, Wu BX, Chen BD, Li KT, Liu YD, Xu Y et al (2022) Compositional and functional aberrance of the gut microbiota in treatment naïve patients with primary Sjögren’s syndrome. J Autoimmun 134:102958. https://doi.org/10.1016/j.jaut.2022.102958CrossRefPubMed

42.

Li Y, Li Z, Sun W, Wang M, Li M (2022) Characteristics of gut microbiota in patients with primary Sjögren’s syndrome in Northern China. PloS one 17(11):e0277270. https://doi.org/10.1371/journal.pone.0277270CrossRefPubMedPubMedCentral

43.

Wei F, Rong C, Yan C, Cao M, Miao Z, Zhou H (2022) Changes of intestinal flora in patients with Sjogren’s syndrome. Int J Immunol 45(1):15–20. https://rs.yiigle.com/CN231535202201/1351424.htm. (in Chinese)

44.

Xu L (2021) Analysis on the characteristics of intestinal flora in patients with primary biliary cholangitis and Sjögren’s syndrome. Dissertation, Qingdao University. https://doi.org/10.27262/d.cnki.gqdau.2021.000175

45.

Zhang SX (2022) Characteristics of gut microbiota enterotype and their effect on immune system and prognosis in patients with autoimmune diseases. Dissertation, Shanxi Medical University. https://doi.org/10.27288/d.cnki.gsxyu.2022.000003

46.

Mao XJ, Wang J, Zhang MX, Yin XF, Lai NL, Cheng T et al (2020) Structure of intestinal microbial community in patients with Sjögren’s syndrome. Chin J Microecology 32(09):1012–7. https://doi.org/10.13381/j.cnki.cjm.202009005. (in Chinese)

47.

Zhou ZQ (2019) Characteristics of intestinal flora in patients with primary Sjogren’s syndrome with deficiency of both qi and yin. Dissertation, Zhejiang Chinese Medical University

48.

Zhao H, Xu H, Chen S, He J, Zhou Y, Nie Y (2021) Systematic review and meta-analysis of the role of Faecalibacterium prausnitzii alteration in inflammatory bowel disease. J Gastroenterol Hepatol 36(2):320–8. https://doi.org/10.1111/jgh.15222CrossRefPubMed

49.

Tochio T, Kadota Y, Tanaka T, Koga Y (2018) 1-Kestose, the smallest fructooligosaccharide component, which efficiently stimulates Faecalibacterium prausnitzii as well as Bifidobacteria in humans. Foods 7(9):140. https://doi.org/10.3390/foods7090140

50.

Rivière A, Selak M, Lantin D, Leroy F, De Vuyst L (2016) Bifidobacteria and Butyrate-producing colon bacteria: importance and strategies for their stimulation in the human gut. Front Microbiol 7:979. https://doi.org/10.3389/fmicb.2016.00979CrossRefPubMedPubMedCentral

51.

Louis P, Flint HJ (2009) Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol Lett 294(1):1–8. https://doi.org/10.1111/j.1574-6968.2009.01514.xCrossRefPubMed

52.

Amoroso C, Perillo F, Strati F, Fantini MC, Caprioli F, Facciotti F (2020) The role of gut microbiota biomodulators on mucosal immunity and intestinal inflammation. Cells 9(5):1234. https://doi.org/10.3390/cells9051234

53.

Fasano A (2011) Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev 91(1):151–75. https://doi.org/10.1152/physrev.00003.2008CrossRefPubMed

54.

Wang Y, Wei J, Zhang W, Doherty M, Zhang Y, Xie H et al (2022) Gut dysbiosis in rheumatic diseases: a systematic review and meta-analysis of 92 observational studies. EBioMedicine 80:104055. https://doi.org/10.1016/j.ebiom.2022.104055CrossRefPubMedPubMedCentral

55.

Jung TH, Park JH, Jeon WM, Han KS (2015) Butyrate modulates bacterial adherence on LS174T human colorectal cells by stimulating mucin secretion and MAPK signaling pathway. Nutr Res Pract 9(4):343–9. https://doi.org/10.4162/nrp.2015.9.4.343CrossRefPubMedPubMedCentral

56.

Lin HV, Frassetto A, Kowalik EJ Jr, Nawrocki AR, Lu MM, Kosinski JR et al (2012) Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PloS one 7(4):e35240. https://doi.org/10.1371/journal.pone.0035240CrossRefPubMedPubMedCentral

57.

Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, Yu D et al (2009) Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 461(7268):1282–6. https://doi.org/10.1038/nature08530CrossRefPubMedPubMedCentral

58.

Fischbach MA, Sonnenburg JL (2011) Eating for two: how metabolism establishes interspecies interactions in the gut. Cell Host Microbe 10(4):336–47. https://doi.org/10.1016/j.chom.2011.10.002CrossRefPubMedPubMedCentral

59.

Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly YM et al (2013) The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341(6145):569–573. https://doi.org/10.1126/science.1241165CrossRefPubMed

60.

Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, deRoos P et al (2013) Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 504(7480):451–5. https://doi.org/10.1038/nature12726CrossRefPubMedPubMedCentral

61.

Sarigul M, Yazisiz V, Bassorgun CI, Ulker M, Avci AB, Erbasan F et al (2010) The numbers of Foxp3 + Treg cells are positively correlated with higher grade of infiltration at the salivary glands in primary Sjogren’s syndrome. Lupus 19(2):138–45. https://doi.org/10.1177/0961203309348234CrossRefPubMed

62.

Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D et al (2013) Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 504(7480):446–50. https://doi.org/10.1038/nature12721CrossRefPubMed

63.

Kugadas A, Wright Q, Geddes-McAlister J, Gadjeva M (2017) Role of microbiota in strengthening ocular mucosal barrier function through secretory IgA. Invest Ophthalmol Vis Sci 58(11):4593–600. https://doi.org/10.1167/iovs.17-22119CrossRefPubMedPubMedCentral

64.

Zaheer M, Wang C, Bian F, Yu Z, Hernandez H, de Souza RG et al (2018) Protective role of commensal bacteria in Sjögren syndrome. J Autoimmun 93:45–56. https://doi.org/10.1016/j.jaut.2018.06.004CrossRefPubMedPubMedCentral

65.

Wang C, Zaheer M, Bian F, Quach D, Swennes AG, Britton RA et al (2018) Sjögren-like lacrimal keratoconjunctivitis in germ-free mice. Int J Mol Sci 19(2). https://doi.org/10.3390/ijms19020565

66.

Yun SW, Son YH, Lee DY, Shin YJ, Han MJ, Kim DH (2021) Lactobacillus plantarum and Bifidobacterium bifidum alleviate dry eye in mice with exorbital lacrimal gland excision by modulating gut inflammation and microbiota. Food Funct 12(6):2489–97. https://doi.org/10.1039/d0fo02984jCrossRefPubMed

67.

Moon J, Ryu JS, Kim JY, Im SH, Kim MK (2020) Effect of IRT5 probiotics on dry eye in the experimental dry eye mouse model. PloS one 15(12):e0243176. https://doi.org/10.1371/journal.pone.0243176CrossRefPubMedPubMedCentral

68.

Cao Y, Lu H, Xu W, Zhong M (2023) Gut microbiota and Sjögren’s syndrome: a two-sample Mendelian randomization study. Front Immunol 14:1187906. https://doi.org/10.3389/fimmu.2023.1187906CrossRefPubMedPubMedCentral

69.

Deschasaux M, Bouter KE, Prodan A, Levin E, Groen AK, Herrema H et al (2018) Depicting the composition of gut microbiota in a population with varied ethnic origins but shared geography. Nat Med 24(10):1526–31. https://doi.org/10.1038/s41591-018-0160-1CrossRefPubMed

70.

He Y, Wu W, Zheng HM, Li P, McDonald D, Sheng HF et al (2018) Regional variation limits applications of healthy gut microbiome reference ranges and disease models. Nat Med 24(10):1532–5. https://doi.org/10.1038/s41591-018-0164-xCrossRefPubMed

71.

Kumar M, Babaei P, Ji B, Nielsen J (2016) Human gut microbiota and healthy aging: recent developments and future prospective. Nutr Healthy Aging 4(1):3–16. https://doi.org/10.3233/nha-150002CrossRefPubMedPubMedCentral

72.

Bolnick DI, Snowberg LK, Hirsch PE, Lauber CL, Org E, Parks B et al (2014) Individual diet has sex-dependent effects on vertebrate gut microbiota. Nat Commun 5:4500. https://doi.org/10.1038/ncomms5500CrossRefPubMed

73.

Brito-Zerón P, Acar-Denizli N, Zeher M, Rasmussen A, Seror R, Theander E et al (2017) Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren’s syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium. Ann Rheum Dis 76(6):1042–50. https://doi.org/10.1136/annrheumdis-2016-209952CrossRefPubMed

74.

Haugen AJ, Peen E, Hultén B, Johannessen AC, Brun JG, Halse AK et al (2008) Estimation of the prevalence of primary Sjögren’s syndrome in two age-different community-based populations using two sets of classification criteria: the Hordaland Health Study. Scand J Rheumatol 37(1):30–4. https://doi.org/10.1080/03009740701678712CrossRefPubMed

75.

Ramirez J, Guarner F, Bustos Fernandez L, Maruy A, Sdepanian VL, Cohen H (2020) Antibiotics as major disruptors of gut microbiota. Front Cell Infect Microbiol 10:572912. https://doi.org/10.3389/fcimb.2020.572912CrossRefPubMedPubMedCentral

76.

Ianiro G, Tilg H, Gasbarrini A (2016) Antibiotics as deep modulators of gut microbiota: between good and evil. Gut 65(11):1906–15. https://doi.org/10.1136/gutjnl-2016-312297CrossRefPubMed

77.

Ferrocino I, Di Cagno R, De Angelis M, Turroni S, Vannini L, Bancalari E et al (2015) Fecal microbiota in healthy subjects following omnivore, vegetarian and vegan Diets: culturable populations and rRNA DGGE profiling. PloS one 10(6):e0128669. https://doi.org/10.1371/journal.pone.0128669CrossRefPubMedPubMedCentral

78.

Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA et al (2011) Linking long-term dietary patterns with gut microbial enterotypes. Science 334(6052):105–108. https://doi.org/10.1126/science.1208344

79.

De Filippis F, Pellegrini N, Laghi L, Gobbetti M, Ercolini D (2016) Unusual sub-genus associations of faecal Prevotella and Bacteroides with specific dietary patterns. Microbiome 4(1):57. https://doi.org/10.1186/s40168-016-0202-1CrossRefPubMedPubMedCentral

80.

Zimmer J, Lange B, Frick JS, Sauer H, Zimmermann K, Schwiertz A et al (2012) A vegan or vegetarian diet substantially alters the human colonic faecal microbiota. Eur J Clin Nutr 66(1):53–60. https://doi.org/10.1038/ejcn.2011.141CrossRefPubMed

81.

Wensel CR, Pluznick JL, Salzberg SL, Sears CL (2022) Next-generation sequencing: insights to advance clinical investigations of the microbiome. J Clin Investig 132(7). https://doi.org/10.1172/jci154944

82.

Mizrahi-Man O, Davenport ER, Gilad Y (2013) Taxonomic classification of bacterial 16S rRNA genes using short sequencing reads: evaluation of effective study designs. PloS one 8(1):e53608. https://doi.org/10.1371/journal.pone.0053608CrossRefPubMedPubMedCentral

83.

Jovel J, Patterson J, Wang W, Hotte N, O’Keefe S, Mitchel T et al (2016) Characterization of the gut microbiome using 16S or shotgun metagenomics. Front Microbiol 7:459. https://doi.org/10.3389/fmicb.2016.00459CrossRefPubMedPubMedCentral

Titel: Association between primary Sjögren’s syndrome and gut microbiota disruption: a systematic review and meta-analysis
verfasst von: Yue Shen
Xue Yu
Qiao Wang
Xinyi Yao
Dingqi Lu
Donghai Zhou
Xinchang Wang
Publikationsdatum: 08.09.2023
Verlag: Springer International Publishing
Erschienen in: Clinical Rheumatology / Ausgabe 2/2024
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-023-06754-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2024

Invasive fungal infection in ANCA-associated vasculitis: Between the Devil and Deep blue sea. Case series and review of the literature

Correction to: An online survey of the Spanish Lupus Patient Association (FELUPUS): patient perceptions and experiences

Correction to: Burnout syndrome among rheumatologists and rheumatology fellows in Arab countries: an ArLAR multinational study

Content analysis of patient support groups related to myositis on Facebook

Understanding muscle coordination during gait based on muscle synergy and its association with symptoms in patients with knee osteoarthritis